Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80

Benzinga Newsdesk www.benzinga.com Positive 57.7%

Neg 0% Neu 0% Pos 57.7%

Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Buy rating and announces Price Target of $80.